A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the response rate of MLN8237 in patients with histologically
confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC). MLN8237
is an orally administered Aurora kinase A inhibitor that has demonstrated broad antitumor
activity in vitro and in vivo. In preclinical models, aurora kinase inhibition resulted in
dramatic and preferential anti-tumor activity in NEPC with suppression of neuroendocrine
marker expression.